Vista Pharmaceuticals Complete Financial Statements
In FY2026, Vista Pharmaceuticals (VISTAPH) reported revenue ₹5 Cr, net profit ₹-16 Cr and EPS ₹-1.96, with a net profit margin of -320.0% and ROE of -44.4%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse Vista Pharmaceuticals ownership structure to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
VISTAPH Revenue, Net Profit & EBITDA — Year-on-Year Growth
VISTAPH YoY (March 2025 vs March 2026) — revenue -54.5%, net profit -220.0%, EBITDA -275.0%, expenses +42.9%. Also explore VISTAPH stock price history to track price trends across different timeframes.
VISTAPH Income Statement — Revenue, EBITDA & Net Profit
Vista Pharmaceuticals revenue ₹5 Cr, EBITDA ₹-15 Cr, net profit ₹-16 Cr, EPS ₹-1.96 (2026) — net profit margin -320.0%. For live price, earnings ratios and company overview, see Vista Pharmaceuticals share price today.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 11 | 11 | 1 | 1 | 2 | 27 | 34 | 29 | 24 | 15 | 14 |
| Expenses | 20 | 14 | 14 | 5 | 2 | 3 | 28 | 30 | 24 | 21 | 13 | 11 |
| EBITDA | -15 | -4 | -3 | -4 | -1 | -2 | -1 | 4 | 6 | 3 | 3 | 3 |
| Operating Profit Margin % | -271.00% | -40.00% | -32.00% | -443.00% | -321.00% | -137.00% | -21.00% | 4.00% | 18.00% | 13.00% | 17.00% | 20.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 |
| Profit Before Tax | -16 | -5 | -5 | -6 | -3 | -4 | -4 | 1 | 3 | 1 | 1 | 1 |
| Tax | 0 | -1 | -1 | 0 | -2 | -2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | -16 | -5 | -5 | -6 | -1 | -2 | -4 | 1 | 2 | 1 | 1 | 1 |
| Earnings Per Share (₹) | -1.96 | -0.79 | -1.03 | -1.54 | -0.24 | -0.54 | -1.22 | 0.31 | 0.76 | 0.46 | 0.31 | 0.54 |
VISTAPH Balance Sheet — Assets, Liabilities & Shareholders' Equity
VISTAPH total assets ₹55 Cr, total equity ₹36 Cr, total liabilities ₹ Cr (2026) — ROE -44.4%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 55 | 60 | 58 | 56 | 56 | 51 | 51 | 53 | 53 | 42 | 26 | 23 |
| Current Assets | 15 | 25 | 23 | 24 | 24 | 15 | 21 | 23 | 28 | 26 | 16 | 12 |
| Fixed Assets | 29 | 19 | 19 | 20 | 19 | 20 | 21 | 21 | 18 | 14 | 10 | 11 |
| Capital Work in Progress | 11 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 7 | 2 | 0 | 0 |
| Investments | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 31 | 29 | 27 | 27 | 22 | 22 | 24 | 28 | 26 | 16 | 12 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 2 | 3 | 3 | 5 | 8 | 9 | 6 | 6 | 6 | 6 | 8 | 0 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 36 | 45 | 41 | 37 | 36 | 33 | 30 | 36 | 32 | 17 | 11 | 10 |
| Share Capital | 12 | 12 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 5 |
| Reserves & Surplus | 24 | 33 | 26 | 23 | 28 | 26 | 24 | 30 | 26 | 11 | 6 | 5 |
VISTAPH Cash Flow Statement — Operating, Investing & Financing
Vista Pharmaceuticals operating cash flow ₹-7 Cr, investing ₹0 Cr, financing ₹8 Cr, net cash flow ₹1 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -7 | -5 | -2 | -1 | -7 | 1 | 3 | -5 | 3 | -3 | -4 |
| Investing Activities | 0 | -1 | -1 | 0 | 0 | -2 | -6 | -11 | -4 | 0 | 0 |
| Financing Activities | 8 | 6 | 3 | 1 | 7 | 0 | 1 | 11 | 6 | 3 | 4 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | -1 | -1 | -4 | 5 | 0 | 0 |